Rushania I. Gabidullina

Rushania I. Gabidullina

Auto-generated profile, based on publicly available information

Rushania I. Gabidullina

Kazan State Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
RGRushania I. Gabidullina
Rushania I. Gabidullina
AKAngelina I. Kuptsova
Angelina I. Kuptsova
EKEkaterina A. Koshelnikova
Ekaterina A. Koshelnikova
FNFikret R. Nuhbala
Fikret R. Nuhbala
RBRufat R. Bagirli
Rufat R. Bagirli
EKEndzhe A. Khaliullina
Endzhe A. Khaliullina
Aim. To investigate the modern condition of the problem of adenomyosis and its impact on womens reproductive function. Material and methods. The article presents a systematic literature review on the results of research search in electronic databases MEDLINE, PubMed, EMBASE, Cochrane Library and Elibrary. Results. Adenomyosis is a common but insufficiently studied disease. Modern imaging methods, such as transvaginal ultrasound and MRI, make it possible to diagnose adenomyosis at the early stages of the disease and perform the organ-preserving surgery. A medical treatment of adenomyosis requires to develop a lifelong management plan, the choice depends on the womans age, reproductive status and clinical symptoms. Currently, there is evidence of a negative impact of adenomyosis on fertility and pregnancy outcomes. Dienogest, a 19-norsteroid derivative, is a progestin with high selectivity to progesterone receptors, it exerts a hypogonadotropic effect and an antiproliferative effect on the endometrium. A mild regime of supression of ovarian function provides adequate conditions for blood supply to the uterus before planning a pregnancy. The immunomodulating effect of progestin may be useful for implantation and fetal protection to pregnancies occurring after treatment. Dienogest treatment increases the effectiveness of IVF cycles for adenomyosis of varying severity. Conclusion. The review summarizes the aspects of prevalence, comorbidity, risk factors, classification, mechanism of pathogenesis, clinical manifestations, diagnosis, treatment of adenomyosis, impact on fertility and pregnancy outcomes.

15 February 2021 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
RGRushania I. Gabidullina
Rushania I. Gabidullina
EKEkaterina A. Koshelnikova
Ekaterina A. Koshelnikova
TSTatiana N. Shigabutdinova
Tatiana N. Shigabutdinova
EMEvgenii A. Melnikov
Evgenii A. Melnikov
GKGulfiria N. Kalimullina
Gulfiria N. Kalimullina
AKAngelina I. Kuptsova
Angelina I. Kuptsova
Aim. To investigate the modern condition of the problem of infertility and obstetric complications in endometriosis and the main management aspects of women with endometriosis in pregnancy planning. Materials and methods. The article presents a systematic literature review on the results of search for studies in electronic databases MEDLINE, PubMed, EMBASE, Cochrane Library and eLibrary. Results. Endometriosis is one of the most common causes of infertility. A cascade of adverse reactions caused by endometriosis prevents a successful pregnancy. Currently, there is an evidence that patients with endometriosis have a high risk of several obstetric complications, such as spontaneous miscarriage, premature birth, preeclampsia, low birth weight and gestational diabetes. Progestogens belong to the first line of therapy of endometriosis, and dydrogesterone is a drug that meets all the necessary requirements. The use of dydrogesterone in the treatment of endometriosis helps to reduce the negative symptoms of endometriosis, improve the quality of life and increase fertility. Dydrogesterone is the only progestogen that has two effective regimens for endometriosis, which allows prescribing therapy for women who are planning pregnancy and for those who have already realized their reproductive plans. Dydrogesterone is the only progestogen that has been suggested to increase the chances of pregnancy in women with endometriosis. Dydrogesterone has been shown to be effective in supporting the luteal phase in ART programs, treating threatening and recurrent miscarriages. Conclusion. Endometriosis is associated with infertility and a high risk of obstetric complications. Dydrogesterone has a number of advantages compared to other progestogens.

26 November 2021 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
RGRushania I. Gabidullina
Rushania I. Gabidullina
AGAlbina V. Ganeeva
Albina V. Ganeeva
TSTatiana N. Shigabutdinova
Tatiana N. Shigabutdinova
Aim. To examine the current state of the problem of the prediction of preeclampsia in early pregnancy. Materials and methods. The article provides an overview of publications based on search results in electronic resources PubMed, Elibrary, EMBASE and Google Scholar. Results. The currently known predictors of preeclampsia can be divided into biochemical and hemodynamic. A number of markers demonstrate prognostic value already in the early stages of gestation. To predict preeclampsia, algorithms are created. They include various combinations of its predictors and maternal risk factors. Conclusion. Prediction of preeclampsia is gradually moving from theory to practice. The instruments of its early forecasting before the gestational age of 14 weeks 6 days are becoming available. That opens up opportunities for targeted and timely prevention of preeclampsia.

14 January 2026 in Kazan medical journal
Verified
Journal Article
Open access
PDF file
NYNikita V. Yakovlev
Nikita V. Yakovlev
RGRushania I. Gabidullina
Rushania I. Gabidullina
SISaule Issenova
Saule Issenova
ИШИсенова Сауле Шакеновна
Исенова Сауле Шакеновна
Gestational weight gain may affect the health of a woman and her child in the short and long term. Both inadequate and excessive weight gain are associated with several adverse pregnancy and delivery outcomes for the mother and fetus. However, optimal ranges of weight gain during pregnancy remain unclear and insufficiently studied for all categories of pregestational body mass index. This review aimed to examine the relationship between ranges of gestational weight gain and the risk of adverse maternal and fetal outcomes. It also aimed to assess the specific features of gestational weight gain based on pregestational body mass index and which strategies can optimize it. The source search was conducted in eLibrary.Ru, PubMed, Medline, Crossref, and Google Scholar databases from 2009 to 2025 using the following keywords: “гестационная прибавка веса” (gestational weight gain), “осложнения беременности” (pregnancy complications), “ожирение” (obesity), “гестационный сахарный диабет” (gestational diabetes mellitus), and “макросомия” (macrosomia). Preference was given to data from randomized controlled trials, systematic reviews, and meta-analyses. Pregestational body mass index is a crucial predictor of favorable pregnancy outcomes. Therefore, it should be considered the primary target for preventing pregnancy and delivery complications associated with excessive body weight and obesity. Inadequate and excessive gestational weight gain are linked to an increased risk of adverse pregnancy and delivery outcomes for the mother (e.g., gestational hypertension, gestational diabetes mellitus, preterm birth, complicated labor, and increased risk of cesarean section) and fetus (e.g., growth disorders, prematurity, and birth trauma). Currently, no unified protocol exists for managing patients with weight changes during preconception care and pregnancy. This is further complicated by regional factors (e.g., place of residence, dietary traditions, and cultural differences) and individual factors (e.g., influence of the immediate social environment, constitutional characteristics, and childhood and adolescent conditions). Population-level studies examining the causes and consequences of variations in gestational weight gain should be continued as they are critical for decreasing maternal and perinatal morbidity and mortality.

23 November 2020 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
RGRushania I. Gabidullina
Rushania I. Gabidullina
MMMarat A. Mingazetdinov
Marat A. Mingazetdinov
EDEvgenya B. Druzhkowa
Evgenya B. Druzhkowa
LSLiaisan I. Sirmatova
Liaisan I. Sirmatova
ДБДружкова Евгения Борисовна
Дружкова Евгения Борисовна
Uterine pyomyoma is a rare and dangerous complication of uterine fibroids, which develops as a result of myomatous node infarction with the addition of an infectious component. In the literature there are descriptions of 50 cases of pyomyomas, half of which are associated with pregnancy. Incorrect diagnosis, lack of antibacterial and surgical treatment can lead to death of the patient. This article describes a clinical case of uterine piomioma development after the first birth by Caesarean section. Method of uterine artery embolization in combination with antibiotic therapy has helped keep the uterus of a young woman. On subsequent observation, menstrual function has fully recovered.

6 July 2025 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
VBVictoria Bitsadze
Victoria Bitsadze
JKJamilya Khizroeva
Jamilya Khizroeva
Elvira GrandoneElvira Grandone
Elvira Grandone
RGR. I. Gabidullina
R. I. Gabidullina
MTMaria V. Tretyakova
Maria V. Tretyakova
AMAlexander Makatsariya
Alexander Makatsariya
Here, we review the current data on the relationship between in vitro fertilization (IVF) procedures and thrombotic complications by focusing on epidemiological, pathophysiological and clinical aspects. Although being a rare IVF complication (incidence is about 0.2 %), thrombosis poses a serious threat especially in patients with ovarian hyperstimulation syndrome (OHSS). The risk of thrombotic complications in OHSS is elevated markedly thereby underscoring the need for careful monitoring and prevention. Despite that arterial thrombosis is less common than venous thrombosis, it is more often associated with OHSS and arise early after ovarian stimulation. IVF is also characterized by atypical thrombosis localization targeting upper limbs, neck and cerebral veins. The risk of thrombogenesis peaks in the first trimester of IVF-related pregnancy and can persist for several weeks after OHSS resolution. Key risk factors for thrombotic complications include OHSS that elevates thrombosis risk by 100-fold; thrombophilia (both hereditary and acquired), especially in women with multiple risk factors; obesity associated with increased estrogens and procoagulant factors level; maternal age > 35 years; polycystic ovary syndrome, which increases VTE risk by five-fold. Special attention is paid to strategies for reducing the risk of thrombotic complications. Compared to fresh embryo transfer, use of revitalized embryos can prominently lower thrombosis risk due to the lack of markedly increased estrogen levels and elimination of OHSS risk.